Odyssey Therapeutics completed an upsized IPO and concurrent private placement, raising $304 million to fund clinical-stage autoimmune and inflammatory pipeline development. The company priced 15.5 million shares at $18 per share and said it will advance OD-001 in ulcerative colitis while planning additional work toward a SLC15A4 program. Separately, Mobia Medical began trading on Nasdaq after pricing its IPO at $15, raising about $150 million for Vivistim Paired VNS, a vagus-nerve stimulation therapy aimed at improving upper-limb function in chronic ischemic stroke survivors. Together, the transactions underscore continued investor appetite for distinct neuromodulation and inflammation franchises with near-term clinical catalysts.